Overview >

Below is a summary of the current status of our three clinical trials.

Severe Coronary Heart Disease (CHD) – A U.S. FDA approved Phase II trial for heart patients with severe coronary heart disease has begun in an expanded patient population in the United States and internationally. We are in the process of finalizing the list of our clinical trial locations for the Phase II severe CHD trial at 30 sites in the United States, Canada and Western Europe. If you are interested in learning more about enrolling in this trial please complete our Clinical Trial Inquiry Form.

The following sites are now open for patient enrollment.

Dermal Wound Healing – CVBT has completed a Phase I trial for wound healing of dermal ulcers in which no serious side effects were noted. The development of a clinical study protocol for initiating a multiple dose safety and efficacy Phase Ib/II trial in an expanded patient population is under way.

Peripheral Artery Disease –The US FDA has authorized a Phase I clinical trial for Peripheral Artery Disease (PAD) specifically for patients with intermittent claudication (cramping pain and weakness in the legs during walking).

Note: While the FDA ultimately determines the course and timing of clinical trials, this timeline represents an estimate as to when certain research milestones could be achieved in the development of those applications. The information is subject to change at any time and is likely to change. Actual results may differ materially. It is provided for information purposes only. Investment decisions should not be made based on the timeline. CVBT does not undertake to update the timeline on this web site. This information is only an estimate.

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2010 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.